Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) earned much-awaited approval on December 19 for the treatment of PD-L1-positive unresectable, advanced or relapsed non-small cell lung cancer (NSCLC) for use in both first-line and second-line settings. Keytruda was approved in Japan in September…
To read the full story
Related Article
- Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





